Example Workshop Saturday, February 16

8:40 am -
Keynote: Migraine; From Hysteria to Neurobiological Entity
Workshop Leader: Daniel Mikol, Executive Medical Director, Global Neuroscience Development Amgen

  • Understand pathophysiology data from imaging studies
  • Summarize new guidelines on developing Acute Treatment for Migraine
  • Assess treatment gaps in Preventive treatment of Migraine and the unmet patient need

Daniel Mikol, Executive Medical Director, Global Neuroscience Development Amgen

Neuroscience Development lead: early/late stage migraine, pipeline products. Development lead for Erenumab (Aimovig) for migraine prevention.

9:00 am - 10:00 am
Workshop A
Workshop Leader: Daniel Mikol, Executive Medical Director, Global Neuroscience Development Amgen Workshop Leader: Sheena Aurora, Medical Fellow Global Launch Leader, Pain Eli Lilly

Working with Migraine Patient Advocacy Organizations on Clinical Trial Design and Recruitment

The patient advocacy perspective is one that is commonly discussed amongst migraine stakeholders, getting the insight from those who work to ensure the migraine awareness is widespread and the outreach to patients is great.

Daniel Mikol, Executive Medical Director, Global Neuroscience Development Amgen

Neuroscience Development lead: early/late stage migraine, pipeline products. Development lead for Erenumab (Aimovig) for migraine prevention.

Sheena-Aurora-Eli-Lilly-47x54

Sheena Aurora, Medical Fellow Global Launch Leader, Pain Eli Lilly

Dr. Aurora received her medical degree from Christian Medical College in India. She interned at Wayne University in Detroit and completed her residency in Neurology at Henry Ford Hospital, also in Detroit. She then completed a fellowship in Headache and Neurophysiology at Henry Ford Hospital. Before coming to Lilly, she was Clinical Associate Professor of Neurology at Stanford University School of Medicine. She joined Lilly in April, 2016 as the Launch Leader for Galcanezumab. Dr. Aurora is board certified in neurology, headache management, and electro diagnostic medicine. She is an active member of several professional societies and has previously served as Chair of the American Academy of Neurology’s Headache Science Working Group; Co-Director of the American Headache Society’s Fall Symposium; and member of the Migraine Research Foundation’s Medical Advisory Board and the National Institute of Neurological Disorders and Stroke’s Working Group. She is also a former Secretary of the American Headache Society. Among Dr. Aurora’s many honors, she received the American Association for the Study of Headache’s Harold G. Wolff Award for Research in Headache (1999, 2001, 2007) and was selected to Seattle Magazine’s list of best doctors (2010, 2011, 2012 and on the list of best doctors in the San Francisco bay area 2015). Dr. Aurora has published more than 90 peer-reviewed manuscripts, most recently in The Journal of Pain, Headache, Acta Neurological Scandinavica, and Journal of Neurology, Neurosurgery, and Psychiatry. She was also one of the principal investigators of the first migraine program project funded by the National Institutes of Health. She lectures internationally on the topics of migraine, headaches, and pain. She continues to be an adjunct clinical associate professor in the Department of Anesthesiology, Perioperative and Pain Medicine at Stanford University in California.

9:00 am - 10:00 am
Workshop B
Workshop Leader: Daniel Mikol, Executive Medical Director, Global Neuroscience Development Amgen

Exploring How To Treat Each Patient, One Size Does Not Fit All

It is important in migraine drug development to look beyond the guidelines and learn from existing successful or unsuccessful trials. How to treat each patient and learn from the trials. Patient management and successful endpoints are critical to trial success.

This workshop will focus on:

  • Managing patients and knowing how to effectively treat at an early stage
  • Improving patient recruitment and retention
  • How to make a trial more attractive and adaptable to the patient
  • Exploration of alternative endpoints, such as functionality as a marker

Daniel Mikol, Executive Medical Director, Global Neuroscience Development Amgen

Neuroscience Development lead: early/late stage migraine, pipeline products. Development lead for Erenumab (Aimovig) for migraine prevention.